March 2, 2011 8:28 AM | 1 min read
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Hapoalim is out with its report on Nektar Therapeutics (NASDAQ: NKTR), lowering its price target from $19 to $17.In a note sent to clients, Hapoalim writes, "Nektar is moving slowly on the planning of its Phase 3 program for NKTR-102 in breast and ovarian cancer, implying 2012 will now be the year that we see major trial results. The company also stated that NKTR-105 will be placed on hold due to development constraints and as a result, we are lowering our Price Target for Nektar from $19 to $17. While NKTR's pipeline has slowed slightly we continue to see long-term value in the name and reiterate our BUY rating."Shares of NKTR closed Tuesday at $9.73, up 1.46% from Monday's close.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.